Digestive System Diseases

All Conditions

Symptoms and General Pathology

Intestinal Diseases

Constipation

Cancer Pain

Pain

Gastrointestinal Diseases

Signs and Symptoms, Digestive

Analgesics

All Drugs and Chemicals

Central Nervous System Depressants

Gastrointestinal Agents

Other Dietary Supplements

Analgesics, Opioid

Benzocaine

Alvimopan

Tannic Acid

0.5 milligrams (mg) of alvimopan was administered orally BID for 3 weeks.

0.5 mg of alvimopan was administered orally QD for 3 days, then 1 mg of alvimopan QD for the remaining 3 weeks. Placebo was administered orally QD to maintain the blind.

A protocol amendment dropped this arm because another study had demonstrated 1 mg QD treatment to have similar efficacy but a less favorable gastrointestinal-related safety profile compared with 0.5 mg BID treatment.

0.5 mg of alvimopan was administered orally BID for 3 days, then 1 mg of alvimopan BID for the remaining 3 weeks.

Placebo was administered orally BID for 3 weeks.

alvimopan

placebo

GSK Clinical Trials, MD

A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain. The study will require five visits over a five-week period.

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects

GlaxoSmithKline

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Spots Global Cancer Trial Database for obd (induced bowel dysfunction)